A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
- Summary
- This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels. This study will consist of two parts (Parts A and B). 56 subjects have been planned for Part A and 141 subjects for Part B. Additional subjects may be included for the optional cohorts depending upon emerging data.
- Short title
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
- Official title
- A Phase I, Randomized, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Single and Multiple Ascending Dose Administration to Healthy Subjects With or Without Elevated LDL-C Levels
- Control arm
- Active comparator
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Completion date
- 2024-06-14
- First posted
- 2022-05-20
- Registry last updated
- 2024-07-19
- Primary completion date
- 2024-06-14
- Start date
- 2022-05-18
- Actual participants
- Participants
- Participant count basis
- Actual
- Protocol amendments
- Randomisation ratio
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- AstraZeneca
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT05384262
- ClinicalTrials.gov ID
- NCT05384262
- Registry record
- Open registry record
- Allocation
- Randomised
- Model
- Parallel groups
- Purpose
- Treatment
- Masking
- Single masking
- Masking description
- This study will be a randomized, single-blind (study center staff including the PI to remain blinded during the dosing phase of each cohort), placebo-controlled, SAD/MAD, sequential group design study in healthy male and/or female subjects, performed at multiple study centers.
- Masked roles
- Participants
Number of subjects with Adverse Events
Timeframe: From Screening (≤ 28 days) until Follow-up Visit (5 to 7 days post-dose for all cohorts, and 9 to 11 days post-dose for subjects from Cohort 3 onwards)
The safety and tolerability of AZD0780 following oral administration of single ascending doses (Part A) and multiple ascending doses (Part B) will be assessed.
Area under plasma concentration time curve from zero to infinity (AUCinf)
Timeframe: SAD cohorts: Day 1-3 until 5-7 days (cohort 1 & 2) & 9-11 days (cohort 3 onwards) post-dose; JSMAD cohorts: Day 1-3,5,8,10,13,15,16 until 7-10 days post-dose; MAD Cohorts: Day 1 to 3,5,8,9,12,15,18,22,25,29 until Days 36, 43 [± 1day]
The single dose and steady state AUCinf of AZD0780 following oral administration of AZD0780 will be assessed.
Area under plasma concentration time curve from zero to t hours post-dose (AUC[0-t])
Timeframe: SAD cohorts: Day 1-3 until 5-7 days (cohort 1 & 2) & 9-11 days (cohort 3 onwards) post-dose; JSMAD cohorts: Day 1-3,5,8,10,13,15,16 until 7-10 days post-dose; MAD Cohorts: Day 1 to 3,5,8,9,12,15,18,22,25,29 until Days 36, 43 [± 1day]
The single dose and steady state AUC(0-t) of AZD0780 following oral administration of AZD0780 will be assessed.
Area under the plasma concentration-curve across the dosing interval (AUCτ)
Timeframe: SAD cohorts: Day 1-3 until 5-7 days (cohort 1 & 2) & 9-11 days (cohort 3 onwards) post-dose; JSMAD cohorts: Day 1-3,5,8,10,13,15,16 until 7-10 days post-dose; MAD Cohorts: Day 1 to 3,5,8,9,12,15,18,22,25,29 until Days 36, 43 [± 1day]
The single dose and steady state AUCτ of AZD0780 following oral administration of AZD0780 will be assessed.
Maximum observed plasma (peak) drug concentration [Cmax]
Timeframe: SAD cohorts: Day 1-3 until 5-7 days (cohort 1 & 2) & 9-11 days (cohort 3 onwards) post-dose; JSMAD cohorts: Day 1-3,5,8,10,13,15,16 until 7-10 days post-dose; MAD Cohorts: Day 1 to 3,5,8,9,12,15,18,22,25,29 until Days 36, 43 [± 1day]
The single dose and steady state Cmax of AZD0780 following oral administration of AZD0780 will be assessed.
Amount of unchanged drug excreted into urine from zero to the last quantifiable concentration by interval and cumulatively (Ae[0-last])
Timeframe: SAD cohorts (Parts A1 & A2): Day 1 to Day 3; JSMAD cohorts (Part B): Day 1 & 15; Global MAD Cohorts Day 1 & 10; Rosuvastatin Global MAD Cohorts (Part B): Day 1 & 8
The single dose and steady state Ae\[0-last\] of AZD0780 following oral administration of AZD0780 will be assessed.
Percentage of dose excreted unchanged in urine from zero to the last quantifiable concentration, by interval and cumulatively (fe[0-last])
Timeframe: SAD cohorts (Parts A1 & A2): Day 1 to Day 3; JSMAD cohorts (Part B): Day 1 & 15; Global MAD Cohorts Day 1 & 10; Rosuvastatin Global MAD Cohorts (Part B): Day 1 & 8
The single dose and steady state fe\[0-last\] of AZD0780 following oral administration of AZD0780 will be assessed.
Renal clearance of drug from plasma (CLR)
Timeframe: SAD cohorts (Parts A1 & A2): Day 1 to Day 3; JSMAD cohorts (Part B): Day 1 & 15; Global MAD Cohorts Day 1 & 10; Rosuvastatin Global MAD Cohorts (Part B): Day 1 & 8
The single dose and steady state CLR of AZD0780 following oral administration of AZD0780 will be assessed.
LDL-C
Timeframe: LDL-C SAD cohorts: Days 1,2,3,5-7,9-11 LDL-C JSMAD cohorts: Days 1,2,3,10,15,16,17;LDL-C Global MAD Cohorts: Days 1,2,3,5,8,12,22, 25,29,36-43;LDL-C Rosuvastatin Global MAD Cohorts:Days -28,-8,-1,1,2,3,5,8,12,15,18,22,29,36-43
The pharmacodynamics (PD) of AZD0780 by assessment of LDL-C following oral administration of single ascending doses (Part A) and multiple ascending doses (Part B) will be assessed.
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Timeframe: PCSK9 SAD cohorts: Days 1,2,3;PCSK9 JSMAD cohorts:Days 1,2,3,10,15,16,17,22-25;PCSK9 Global MAD Cohorts:Days 1,8,15,22,29,36-43; PCSK9 Rosuvastatin Global MAD Cohorts:Days 1,8,15,22,29,36-43
The PD of AZD0780 by assessment of total PCSK9 (and compound stabilized PCSK9 for Part A) following oral administration of single ascending doses (Part A) will be assessed.
- Sex
- All
- Age groups
- Adults
- Minimum age
- 18 Years
- Maximum age
- 55 Years
- Healthy volunteers
- Yes
-
Provision of signed and dated, written informed consent prior to any study specific procedures (including the Pre Screening Visit for Part B).
-
Healthy male and female subjects (of nonchildbearing potential), aged 18 to 55 years inclusive, with suitable veins for cannulation or repeated venipuncture.
-
Females must have a negative pregnancy test at the Screening Visit and on admission to the study center, must not be lactating and must be of non childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria:
- Postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range.
- Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
-
Have a BMI between 18 and 35 kg/m2 inclusive and weigh at least 50 kg and no more than 120 kg inclusive at the Screening Visit and on admission to the study center.
-
For Japanese subjects (Part B) and Chinese subjects (Part A):
- A subject will be considered Japanese if both parents and all grandparents are Japanese, the subject was born in Japan, and the subject has not lived outside Japan for more than 10 years.
- A subject will be considered Chinese if both parents and all grandparents are Chinese, the subject was born in China, and the subject has not lived outside China for more than 10 years.
-
For Part B (MAD), at the Screening Visit subjects must have LDL-C ≥ 70 mg/dL but ≤ 190 mg/dL (or ≥ 1.8 mmol/L but ≤ 4.9 mmol/L for London EPCU [Early Phase Clinical Unit]), and triglycerides < 400 mg/dL (or < 10.3 mmol/L for London EPCU).
-
For Part B (rosuvastatin global MAD), at the Screening Visit subjects must have LDL-C ≥ 100 mg/dL but < 190 mg/dL (≥ 2.6 mmol/L but ≤ 4.9 mmol/L for London EPCU).
- History of any clinically important disease or disorder.
- History or presence of gastrointestinal, hepatic or, renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
- Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first vaccination within 30 days prior to randomization.
- SARS-CoV-2 second vaccination within 10 days of screening.
- Confirmed Coronavirus disease 2019 (COVID-19) infection during screening and admission, by Polymerase Chain Reaction (PCR) test (in the London EPCU, COVID-19 infection before or during Screening and/or admission will be confirmed by a COVID-19 test. Subjects will undergo COVID-19 testing prior to ICF signing and any subject testing positive will not be screened for the study).
- Any clinically important abnormalities in clinical chemistry, coagulation, hematology, or urinalysis results.
- Any positive result on Screening for serum hepatitis B surface antigen, hepatitis C antibody, and Human immunodeficiency virus (HIV).
- Abnormal vital signs after 10 minutes supine rest at the Screening Visit and on admission to the study center.
- Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-lead ECG that may interfere with the interpretation of ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) corrected for heart rate (QTc) interval changes including abnormal ST-T-wave morphology at the Screening Visit and/or on admission to the study center.
- Known or suspected history of drug abuse.
- Current smokers or those who have smoked or used nicotine products within the previous 3 months.
- History of alcohol abuse or excessive intake of alcohol.
- Positive screen for drugs of abuse, cotinine (nicotine), or alcohol at Screening and/or admission to the study center.
- History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0780.
- Excessive intake of caffeine-containing drinks or food.
- Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
- Use of any prescribed or nonprescribed medication including antacids, analgesics, herbal remedies, mega-dose vitamins, and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life.
- Plasma donation within one month of the Screening Visit or any blood donation/blood loss during the 3 months prior to the Screening Visit.
- Has received another new chemical entity within 30 days or 5 half-lives of the first administration of IMP in this study.
- Subjects who have previously received AZD0780 within 60 days of the first administration of IMP in this study.
- Involvement of any Astra Zeneca or study center employee or their close relatives.
- Any ongoing or recent minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
- Subjects who are vegans or have medical dietary restrictions.
- Subjects who cannot communicate reliably with the investigator.
- Vulnerable subjects.
- Research SiteGlendale, United States
- Research SiteBrooklyn, United States
- Research SiteHarrow, United Kingdom
- PubMed 42137960Related publication
Other registry identifiers
- 2022-002221-10
Related records
Drugs (2)
Collaborators (1)
- Parexel